Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 360 participants.
Also called NCT04160000
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 360 participants
- Sponsor
- Electrophysiology Research Foundation
- Registry
-
NCT04160000
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Germany, Switzerland
- Registry status
- Unknown status
Technical summary
Registry record NCT04160000. Randomized; no masking; primary purpose treatment. Start 2020-07-26 (actual); primary completion 2024-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
- Acronym
- TAP-CHF
- Condition
- Atrial Fibrillation
- Condition
- Heart Failure
- Condition
- Diastolic Heart Failure
- Intervention (Device)
- Catheter ablation
- Intervention (Drug)
- Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation
- Intervention (Device)
- Insertion of CardioMems Hemodynamic monitor
- Intervention (Drug)
- Empiric heart failure drug therapy
- Lead sponsor
- Electrophysiology Research Foundation
Record details
- Record id
cardio:ct-nct04160000- Content hash
085476d4ce5204ee0233a93e81d590aed9ad5056182346c31d63272f883c66ee